

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/236134 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2022/028189

(22) International Filing Date:
06 May 2022 (06.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/185,989 07 May 2021 (07.05.2021) US
63/203,688 28 July 2021 (28.07.2021) US
63/277,035 08 November 2021 (08.11.2021) US

(71) Applicant: SURFACE ONCOLOGY, INC. [US/US]; 50
Hampshire Street, 8th Floor, Cambridge, Massachusetts
02139 (US).

(72) Inventors: O'NEILL, Alison; c/o Surface Oncology, Inc.,
50 Hampshire Street, 8th Floor, Cambridge, Massachusetts
02139 (US). HARSHMAN, Lauren; c/o Surface Oncolo-
gy, Inc., 50 Hampshire Street, 8th Floor, Cambridge, Mass-
achusetts 02139 (US). HILL, Jonathan; c/o Surface On-
cology, Inc., 50 Hampshire Street, 8th Floor, Cambridge,
Massachusetts 02139 (US). CHUNG, Jou-Ku; c/o Surface
Oncology, Inc., 50 Hampshire Street, 8th Floor, Cambridge,
Massachusetts 02139 (US). WHITE, Kerry; c/o Surface
Oncology, Inc., 50 Hampshire Street, 8th Floor, Cambridge,
Massachusetts 02139 (US). ROSS, Robert; c/o Surface On-
cology, Inc., 50 Hampshire Street, 8th Floor, Cambridge,
Massachusetts 02139 (US). LEE, Benjamin; c/o Surface
Oncology, Inc., 50 Hampshire Street, 8th Floor, Cambridge,
Massachusetts 02139 (US).

(74) Agent: KIM, Ji Eun et al.; Sterne, Kessler, Goldstein &
Fox P.L.L.C., 1100 New York Avenue, NW, Washington,
District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-IL-27 ANTIBODIES AND USES THEREOF

(57) Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or anti-
gen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.

WO 2022/236134 A1